Senores Pharmaceuticals Allots Warrants in Preferential Issue
Senores Pharmaceuticals Limited announced the allotment of 11,70,000 warrants convertible into equity shares on a preferential basis. The decision, made at a board meeting held on March 28, 2026, follows approvals from members on January 31, 2026, and in-principle approvals from the BSE Limited and National Stock Exchange of India Limited on March 13, 2026.The warrants, each carrying the right to subscribe to one equity share, have an exercise price of ₹812 per warrant. The total value of the allotment aggregates to ₹95,00,40,000. Allottees paid ₹203 per warrant, amounting to ₹23,75,10,000, at the time of allotment.
The warrants were allotted to:
| Name of the Allottee's | Category | Warrants Allotted |
|---|---|---|
| Swapnil Jatin Shah | Promoter | 1,97,000 |
| Ashokbhai Vijaysinh Barot | Promoter | 1,23,000 |
| Renosen Pharmaceuticals Private Limited | Promoter Group | 7,39,000 |
| Sangeeta Mukur Barot | Promoter Group | 61,500 |
| Viraj Ashokkumar Barot | Promoter Group | 49,500 |
| Total | Total | 11,70,000 |
The warrants are subject to lock-in restrictions as prescribed under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
The board meeting commenced at 11:45 A.M. (IST) and concluded at 12:07 P.M. (IST).
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.